Philip Morris appoints Jorge Insuasty President of Vectura Fertin Pharma; adjusts de Wilde's compensation
Philip Morris International Inc.
- Jorge Insuasty appointed full-time President, Vectura Fertin Pharma effective Jan 1, 2023; continues reporting to CEO Jacek Olczak.
- Insuasty steps down as Chief Life Sciences Officer; Badrul Chowdhury now reports directly to CEO as Chief Life Sciences Officer, Smoke-Free Products.
- Frederic de Wilde appointed President of SSEA, CIS, MEA region; base salary increased to CHF 1,000,008 (approx. $1,080,009).
- de Wilde's annual incentive target set at 125% of base salary; equity award target at 275% of base salary.